Skip NavigationSkip to Content
Return Return to Search Results

Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production

  1. Author:
    Seol, H. S.
    Lee, S. E.
    Song, J. S.
    Lee, H. Y.
    Park, S.
    Kim, I.
    Singh, S. R.
    Chang, S.
    Jang, S. J.

  2. Author Address

    Asan Institute for Life Science, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Basic Research Laboratory, Stem Cell Regulation and Animal Aging Section, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov. Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address: suhwan.chang@amc.seoul.kr. Asan Institute for Life Science, Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address: jangsejin@amc.seoul.kr.
    1. Year: 2016
    2. Date: 28-Nov
    3. Epub Date: 10/25/2016
  2. Journal: Cancer Letters
    1. 382
    2. 2
    3. Pages: 157-165
  4. Type of Article: Article
  5. ISSN: 0304-3835
  1. Abstract:

    Liver cancer is one of the common malignancies in many countries and an increasing cause of cancer death. Despite of that, there are few therapeutic options available with inconsistent outcome, raising a need for developing alternative therapeutic options. Through a drug repositioning screening, we identified and investigated the action mechanism of the Riluzole, an amyotrophic lateral sclerosis (ALS) drug, on hepatocellular carcinoma (HCC) therapy. Treatment of the Riluzole leads to a suppression of cell proliferation in liver primary cancer cells and cancer cell lines. In addition, Riluzole induced caspase-dependent apoptosis and G2/M cell cycle arrest in SNU449 and Huh7 cell lines. In a line with the known function of glutamate release inhibitor, we found Riluzole-treated cells have increased the level of inner cellular glutamate that in turn decrease the glutathione (GSH) level and finally augment the reactive oxygen species (ROS) production. We confirm this finding in vivo by showing the Riluzole-induced GSH and ROS changes in a Huh7 xenograft cancer model. Altogether, these data suggest the anti-cancer effect of Riluzole on hepatocellular carcinoma and the suppression of glutamate signaling might be a new target pathway for HCC therapy.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.canlet.2016.08.028
  3. PMID: 27612558
  4. View record in Web of Science®
  5. WOS: 000387199000003

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel